Rule2025-16629
Advisory Committee; Arthritis Advisory Committee; Termination; Removal From List of Standing Committees
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
August 29, 2025
Effective
August 29, 2025
Issuing agencies
Health and Human Services DepartmentFood and Drug Administration
Abstract
The Food and Drug Administration (FDA or the Agency) is announcing the termination of the Arthritis Advisory Committee (Committee). Due to that termination, this final rule removes the Committee from the Agency's list of standing advisory committees in 21 CFR 14.100.
Full Text
<html>
<head>
<title>Federal Register, Volume 90 Issue 166 (Friday, August 29, 2025)</title>
</head>
<body><pre>
[Federal Register Volume 90, Number 166 (Friday, August 29, 2025)]
[Rules and Regulations]
[Pages 42134-42135]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2025-16629]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Part 14
[Docket No. FDA-2025-N-2427]
Advisory Committee; Arthritis Advisory Committee; Termination;
Removal From List of Standing Committees
AGENCY: Food and Drug Administration, HHS.
ACTION: Final rule.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or the Agency) is
announcing the termination of the Arthritis Advisory Committee
(Committee). Due to that termination, this final rule removes the
Committee from the Agency's list of standing advisory committees in 21
CFR 14.100.
DATES: This rule is effective August 29, 2025.
FOR FURTHER INFORMATION CONTACT: Emily Helms Williams, Director,
Advisory Committee Oversight and Management Staff, Office of the Chief
Scientist, Food and Drug Administration, 10903 New Hampshire Ave.,
Bldg. 1, Silver Spring, MD 20993-0002, 301-796-3381,
<a href="/cdn-cgi/l/email-protection#d89db5b1b4a1f690bdb4b5ab8fb1b4b4b1b9b5ab98bebcb9f6b0b0abf6bfb7ae"><span class="__cf_email__" data-cfemail="c287afabaebbec8aa7aeafb195abaeaeaba3afb182a4a6a3ecaaaab1eca5adb4">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: The Arthritis Advisory Committee was
established on April 5, 1974 (39 FR 14737), to advise the Commissioner
of Food and Drugs or designee in discharging responsibilities as they
relate to helping to ensure safe and effective drugs for human use in
arthritic conditions, and as required, any other product for which FDA
has regulatory responsibility.
This Committee has met infrequently in recent years, and FDA has
determined that the effort and expense of maintaining the Committee is
no longer justified. The Committee was terminated on July 30, 2025 (90
FR 35876). Therefore, the Agency is amending 21 CFR 14.100 to remove
the Committee's name and function from its current list of standing
advisory committees, as set forth in the regulatory text of this
document.
Under 5 U.S.C. 553(b)(4)(B) and (d) and 21 CFR 10.40(d) and (e),
the Agency finds good cause to dispense with notice and public comment
procedures and to proceed to an immediate effective date on this rule.
Notice and public comment and a delayed effective date are
unnecessary and are not in the public interest as this
[[Page 42135]]
final rule is merely codifying the removal of the name and function of
the Committee from the list of standing FDA advisory committees in 21
CFR 14.100. The termination of this Committee is already effective.
Therefore, the Agency is amending Sec. 14.100(c) as set forth in
the regulatory text of the document.
List of Subjects in 21 CFR Part 14
Administrative practice and procedure, Advisory committee, Color
additives, Drugs, Radiation protection.
Therefore, under the Federal Food, Drug, and Cosmetic Act and under
authority delegated to the Commissioner of Food and Drugs, 21 CFR part
14 is amended as follows:
PART 14--PUBLIC HEARING BEFORE A PUBLIC ADVISORY COMMITTEE
0
1. The authority citation for 21 CFR part 14 continues to read as
follows:
Authority: 5 U.S.C. 1001 et seq.; 15 U.S.C. 1451-1461; 21 U.S.C.
41-50, 141-149, 321-394, 467f, 679, 821, 1034; 28 U.S.C. 2112; 42
U.S.C. 201, 262, 263b, 264, 284m, 284m-1; Pub. L. 107-109, 115 Stat.
1419.
Sec. 14.100 [Amended]
0
2. Section 14.100 is amended by removing paragraph (c)(3) and
redesignating paragraphs (c)(4) through (18) as (c)(3) through (17).
Grace R. Graham,
Deputy Commissioner for Policy, Legislation, and International Affairs.
[FR Doc. 2025-16629 Filed 8-28-25; 8:45 am]
BILLING CODE 4164-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on August 29, 2025.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.